An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of <scp>SAR442085</scp> in patients with relapsed or refractory multiple myeloma

The efficacy of SAR442085 was promising in anti-CD38 mAb naïve patients but did not extend to the larger cohort of anti-CD38 mAb pre-treated patients. This observation, along with transient high-grade thrombocytopenia, could potentially limit its clinical use.